{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:31:13Z","timestamp":1794623473763,"version":"4.9.1"},"reference-count":74,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Prurigo nodularis (PN) is a chronic dermatological condition characterized by intensely pruritic nodules resulting from repeated scratching. Its pathogenesis involves neuroimmune dysregulation, inflammatory cytokines, and neural proliferation. Conventional treatments often provide limited relief, necessitating novel therapeutic approaches. This narrative review explores emerging biologics and small molecules for PN treatment, assessing their mechanisms, efficacy, and safety. A comprehensive literature search was conducted using PubMed, Google Scholar, and Web of Science for relevant studies up to February 2025. Additionally, ongoing clinical trials were identified through a verified international website. The search terms included \u201cprurigo nodularis\u201d, \u201cbiologic treatments\u201d, \u201cmonoclonal antibodies\u201d, \u201csmall molecules\u201d, and \u201cJAK inhibitors\u201d. Among new treatment options, dupilumab, an IL-4 receptor antagonist, and nemolizumab, an IL-31 receptor inhibitor, demonstrated significant efficacy in reducing pruritus and lesion severity in PN patients. Other promising monoclonal antibodies include vixarelimab (OSMR\u03b2 inhibitor) and barzolvolimab (KIT inhibitor). Small molecules such as JAK inhibitors (upadacitinib, povorcitinib) also show potential by modulating inflammatory pathways. Clinical trials highlight their efficacy, safety, and long-term benefits. Emerging biologics and small molecules represent a transformative approach for PN management, offering targeted therapies that address underlying immunological and neurological mechanisms. Ongoing research and long-term studies are crucial to optimizing treatment strategies and improving patient outcomes.<\/jats:p>","DOI":"10.3390\/medicina61040631","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:21:04Z","timestamp":1743398464000},"page":"631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9859-4475","authenticated-orcid":false,"given":"Matteo","family":"Bianco","sequence":"first","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3446-6648","authenticated-orcid":false,"given":"Francesco","family":"D\u2019Oria","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Falcidia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0527-706X","authenticated-orcid":false,"given":"Giulio","family":"Foggi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Matteodo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3780-5318","authenticated-orcid":false,"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Facheris","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-4866","authenticated-orcid":false,"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Perugini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-8710","authenticated-orcid":false,"given":"Carlo Alberto","family":"Vignoli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: New insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"adv00309","DOI":"10.2340\/00015555-3655","article-title":"Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis","volume":"100","author":"Ketz","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMe1916733","article-title":"Breaking the Itch-Scratch Cycle in Prurigo Nodularis","volume":"382","author":"Kwatra","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/abd1806-4841.20187127","article-title":"Xerosis cutis and associated co-factors in women with prurigo nodularis","volume":"93","author":"Akarsu","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jaad.2023.06.045","article-title":"Prevalence and comorbidity burden of prurigo nodularis in United States adults enrolled in the All of Us research program","volume":"89","author":"Joel","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.jid.2023.04.033","article-title":"A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis","volume":"143","author":"Vasavda","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_7","first-page":"53","article-title":"Psychiatric Comorbidity in Prurigo Nodularis and the Impact of Socioeconomic Status","volume":"15","author":"Han","year":"2022","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13555-025-01349-7","article-title":"Healthcare Resource Utilization and Economic Burden of Prurigo Nodularis in the United States","volume":"15","author":"Kwatra","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2023.04.015","article-title":"Prevalence of tuberculosis in patients with prurigo nodularis: A multicenter cross-sectional study","volume":"89","author":"Cornman","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: Pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archderm.1993.01680280049009","article-title":"Mast cells, neutrophils, and eosinophils in prurigo nodularis","volume":"129","author":"Perez","year":"1993","journal-title":"Arch. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"adv00269","DOI":"10.2340\/00015555-3571","article-title":"Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment","volume":"100","author":"Pereira","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40265-021-01521-1","article-title":"IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses","volume":"81","author":"Roh","year":"2021","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hughes, J.-D.M., Woo, T.E., Belzberg, M., Khanna, R., Williams, K.A., Kwatra, M.M., Hassan, S., and Kwatra, S.G. (2020). Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis. Medicines, 7.","DOI":"10.3390\/medicines7010004"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yook, H.J., and Lee, J.H. (2024). Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105164"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/09546630903386606","article-title":"An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis","volume":"21","author":"Saraceno","year":"2010","journal-title":"J. Dermatolog Treat."},{"key":"ref_19","first-page":"31","article-title":"Pimecrolimus cream 1%: A potential new treatment for chronic hand dermatitis","volume":"73","author":"Belsito","year":"2004","journal-title":"Cutis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jdv.14646","article-title":"Treatment of prurigo with methotrexate: A multicentre retrospective study of 39 cases","volume":"32","author":"Klejtman","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaad.2016.02.1237","article-title":"Gabapentin and pregabalin for the treatment of chronic pruritus","volume":"75","author":"Matsuda","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","article-title":"Butorphanol for treatment of intractable pruritus","volume":"54","author":"Dawn","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2015.09.039","article-title":"Thalidomide for the treatment of chronic refractory pruritus","volume":"74","author":"Sharma","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","article-title":"Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments","volume":"25","author":"Zeidler","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.19794","article-title":"Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study","volume":"38","author":"Avallone","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Olbrich, H., Sadik, C.D., Ludwig, R.J., Tha\u00e7i, D., and Boch, K. (2023). Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules., 13.","DOI":"10.3390\/biom13040634"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat. Med."},{"key":"ref_28","unstructured":"Sanofi (2025, March 01). Real-World Effectiveness of Dupilumab in Patients with Prurigo Nodularis: An Observational Study (GLOBOS-PIN). US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05991323."},{"key":"ref_29","unstructured":"Sanofi (2025, March 01). A Non-interventional Study to Describe the Dupilumab Long-Term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine (CLEAR PN). US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06087627."},{"key":"ref_30","unstructured":"Sanofi (2025, March 01). A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants \u22656 Months to <18 Years of Age with Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06293053."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20406223221112561","DOI":"10.1177\/20406223221112561","article-title":"Increased IL-31 expression in serum and tissue protein in prurigo nodularis","volume":"13","author":"Chaowattanapanit","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial","volume":"161","author":"Yosipovitch","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","unstructured":"Galderma, R.&D. (2025, March 01). A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05052983."},{"key":"ref_35","unstructured":"Galderma (2025, March 01). EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab\u2019s Long-Term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations. Available online: https:\/\/www.galderma.com\/news\/galdermas-nemluvior-nemolizumab-approved-european-union-moderate-severe-atopic-dermatitis-and."},{"key":"ref_36","unstructured":"Galderma, R.&D. (2025, March 01). A Long-Term Study of Nemolizumab (CD14152) in Participants with Prurigo Nodularis (PN). US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04204616."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101826","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: A randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_38","unstructured":"Kiniksa Pharmaceuticals, Ltd. (2025, March 01). Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03816891."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Hawro","year":"2023","journal-title":"Allergy"},{"key":"ref_40","unstructured":"Celldex Therapeutics (2025, March 01). A Study of CDX-0159 in Patients With Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04944862."},{"key":"ref_41","unstructured":"Celldex Therapeutics (2025, March 01). A Study of Barzolvolimab in Patients with Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06366750."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Walig\u00f3ra-Dziwak, K., Da\u0144czak-Pazdrowska, A., and Jenerowicz, D. (2024). A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13144001"},{"key":"ref_43","unstructured":"Amgen (2025, March 01). A Phase 3, Placebo-Controlled, Double-Blind Study Assessing Rocatinlimab in Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06527404."},{"key":"ref_44","unstructured":"Guangdong Hengrui Pharmaceutical Co., Ltd. (2025, March 01). Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06554509."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e13763","DOI":"10.1111\/cts.13763","article-title":"Safety, pharmacokinetics, and pharmacodynamics of anti-IL-4R\u03b1 antibody SHR-1819 in healthy subjects: A randomized, controlled phase I study","volume":"17","author":"Li","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_46","unstructured":"Keymed Biosciences Co., Ltd. (2025, March 01). Study on the Treatment of Prurigo Nodularis With Stapokibart Injection. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06424470."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40259-024-00668-z","article-title":"Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial","volume":"38","author":"Zhao","year":"2024","journal-title":"BioDrugs"},{"key":"ref_48","unstructured":"Shanghai Mabgeek Biotech Co., Ltd. (2025, March 01). Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects with Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06779136."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jaad.2023.04.056","article-title":"Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study","volume":"89","author":"Pezzolo","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","article-title":"Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s13555-018-0258-x","article-title":"Treatment of Atopic Dermatitis with Biologic Drugs","volume":"8","author":"Fabbrocini","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.anai.2023.01.020","article-title":"Oral Janus kinase inhibitors for atopic dermatitis","volume":"130","author":"Mikhaylov","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_55","unstructured":"Incyte Corporation (2025, March 01). A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN1). US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05755438."},{"key":"ref_56","unstructured":"Incyte Corporation (2025, March 01). A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN2). US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05764161."},{"key":"ref_57","unstructured":"Incyte Corporation (2025, March 01). A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06213831."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/10600280221096713","article-title":"Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis","volume":"57","author":"Perche","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_59","unstructured":"Johns Hopkins University (2025, March 01). Efficacy of Abrocitinib for Reducing Pruritus in Adults with Prurigo Nodularis and Chronic Pruritus of Unknown Origin. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05038982."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","article-title":"Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial","volume":"160","author":"Kwatra","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_61","unstructured":"Incyte Corporation (2025, March 01). A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05061693."},{"key":"ref_62","unstructured":"Kwatra, S., Metz, M., and Yosipovitch, G. (2024, January 24\u201328). Efficacy and Safety of Oral Povorcitinib in Patients with Prurigo Nodularis: 40-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Proceedings of the 33rd European Academy of Dermatology and Venereology Congress, Amsterdam, The Netherlands."},{"key":"ref_63","unstructured":"Incyte Corporation (2025, March 01). A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants with Prurigo Nodularis (STOP-PN1). US National Library of Medicine: ClinicalTrials.gov. Identifier: NCT06516952, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06516952?cond=NCT06516952&rank=1."},{"key":"ref_64","unstructured":"Incyte Corporation (2025, March 01). A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants with Prurigo Nodularis (STOP-PN2). US National Library of Medicine: ClinicalTrials.gov. Identifier: NCT06516965, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06516965?cond=NCT06516965&rank=1."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/CCID.S329442","article-title":"Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review","volume":"17","author":"Ibba","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2375102","DOI":"10.1080\/09546634.2024.2375102","article-title":"Upadacitinib 30\u2009mg for the optimal management of moderate-to-severe atopic dermatitis: A 52-week single-center real-world study","volume":"35","author":"Gargiulo","year":"2024","journal-title":"J. Dermatolog Treat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/jdv.19507","article-title":"Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study","volume":"38","author":"Gargiulo","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_69","unstructured":"Psoriasis Treatment Center of Central New Jersey (2025, March 01). Upadacitinib for Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov. Identifier: NCT06773403, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06773403?cond=NCT06773403&rank=1."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jaad.2024.06.094","article-title":"Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study","volume":"91","author":"Pezzolo","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_71","unstructured":"Second Affiliated Hospital, School of Medicine, Zhejiang University (2025, March 01). Efficacy and Safety of Tofacitinib in Patients with Prurigo Nodularis. US National Library of Medicine: ClinicalTrials.gov. Identifier: NCT06201715, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06201715?cond=NCT06201715&rank=1."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1111\/ijd.16568","article-title":"Successful treatment of prurigo nodularis with tofacitinib: The experience from a single center","volume":"62","author":"Liu","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/CCID.S354025","article-title":"Tofacitinib for Prurigo Nodularis: A Case Report","volume":"15","author":"Peng","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"238","DOI":"10.25259\/IJDVL_362_2023","article-title":"Treatment of recalcitrant paediatric prurigo nodularis with tofacitinib, an exquisite example of bench-to-bedside translation of JAK-STAT expression","volume":"90","author":"Sardana","year":"2023","journal-title":"Indian J. Dermatol. Venereol. Leprol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/4\/631\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:41Z","timestamp":1760029541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/4\/631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":74,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["medicina61040631"],"URL":"https:\/\/doi.org\/10.3390\/medicina61040631","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}